2-(4-IODINE-2,5-DIMETHOXYPHENYL)-N-[(2-METHOXYPHENYL)METHYL]ETAMINE OR 25I-NBOMe: CHEMICAL CHRACTERIZATION OF A DESIGNER DRUG

The Use of Single Crystal X-Ray Diffraction Technique for Characterization of 25I-NBOMe and 25R-NBOH (R = Cl, I, Br, Et) in Forensic Application

“…The relevant bands attributed to a 25I-NBOMe sample were observed at 3392 cm -1 , which is in the region of 3600-3200 cm -1 , assigned to the axial deformation N-H of the amine group, 2836 and 2937 cm -1 bands representing the axial strain C-H of carbon sp 3 , groups CH 3 and CH 2 , the band at 1437 cm -1 corresponding to symmetrical angular deformation in the plane of CH 2 , the ether group was characterized by the 1020 cm -1 band, characterizing the intense axial deformation C-O-C. 756 cm -1 band, the disubstituted aromatic ring was identified through the appearance of the band which corresponds to symmetrical angular deformation outside the C-H plane, and the presence of iodine was due to the band 1214 cm -1 , corresponding to axial deformation C-I. 47 The main difference between 25I-NBOH and 25I-NBOMe is the band in 1020 cm -1 assigned to the axial deformation C-O-C.…”

Interpol review of controlled substances 2016–2019

“…NBOMe Compounds: 2016 The detection of NBOMe designer drugs on blotter paper by high resolution time-of-flight mass spectrometry (TOFMS) with and without chromatography [ 1021 ]; case series: toxicity from 25B–NBOMe--a cluster of N-bomb cases [ 1022 ]; HPTLC and GC-MS analysis of 25 C NBOMe in Seized Blotters [ 1023 ]; Detection of 25C–NBOMe using LC-QTOF designer drug screen and quantitated by LC-MS-MS [ 1024 ]; identification of 2,4,6-TMPEA-NBOMe by GC-MS, GC-HRMS, GC-HRMS/MS, UHPLC/HRMS, UHPLC/HRMS/MS, and (1) H and (13) C NMR [ 1025 ]; analytical characterization of 3,4-DMA-NBOMe (1), 4-EA-NBOMe (2), 4-MMA-NBOMe (3), and 5-APB-NBOMe (4) by MS, IR spectroscopic, and NMR spectroscopic data [ 1026 ]; chemical profiling of 25I–NBOMe TLC, UV–Vis, ATR-FTIR, GC-MS and ESI-FT-ICR MS [ 1027 ]; identification of 25X-NBOMe and analogues by GC-MS [ 1028 ]; 2017 Rapid screening and analytical determination of 25B–NBOMe and 25I–NBOMe via Cyclic and Differential Pulse Voltammetry [ 1029 ]; 25B–NBOMe and 25C–NBOMe by GC-MS, LC-MS(n), and LC-HR-MS/MS [ 1030 ]; Identification and quantification of 5 different 25-NBOMes (25B–NBOMe, 25C–NBOMe, 25D-NBOMe, 25H–NBOMe, 25I–NBOMe) via LC-MS-MS [ 1031 ]; synthesis of potential metabolites of 25C–NBOMe and 25I–NBOMe [ 1032 ]; UPLC-QTOF-MS analysis of twelve 2C-X, six 2,5-dimethoxyamphetamines (DOX), and fourteen 25X-NBOMe derivatives, including two deuterated derivatives (2C–B-d(6) and 25I–NBOMe-d(9) [ 1033 ]; identification of NBOMes and the analogous 2,5-dimethoxy phenethylamine structures by voltammetric methods in blotting paper seized from the drug market [ 1034 ]; modification of solvent delay window to prevent misidentification of 25I–NBOH as 2C–I with GC-MS [ 1035 ]; 25c-nbome: Case report and literature review [ 1036 ]; comparison of nano-LC-HRMS/MS to UHPLC for detection of 3,4-DMA-NBOMe and 4-MMA-NBOMe and metabolites [ 1037 ]; 2018 square-wave voltammetry for the quantification of NBOMes and their correlates, 2,5-dimethoxy phenethylamine structures in seized blotting paper [ 1038 ]; the analysis of illicit 25X-NBOMe from over 100 seizures in Western Australia [ 1039 ] ; LC-HR-MS/MS identification of the phase I and II metabolites of 4-EA-NBOMe [ 1040 ]; LC-MS-MS confirmation of 251-NBOMe [ 1041 ]; 2019 handheld NIR spectrometer for discrimination of NBOMe and NBOH drugs absorbed in blotter papers using PLS-DA and SIMCA [ 1042 ]; 2019 SPCE electrochemical method for the detection of 25I–NBOH and full differentiation between 25I–NBOH, 2C–I and 25I–NBOMe [ 1043 ]; review [ 1044 ]; review of the main methods for the analysis of NBOMe compounds for detection in seized and biological materials for forensic a...…”

Desafios analíticos na identificação de drogas sintéticas NBOMe e NBOH no contexto forense: uma revisão bibliográfica

“…Além disso, as designers drugs, outro nome que podem receber, apresentam alterações na sua estrutura química e imitam as ações e os efeitos psicoativos de medicamentos licenciados e outras drogas ilícitas controladas, os quais evidenciam um potencial de abuso muito mais rápido do que as controladas pela legislação vigente e maiores riscos de overdose. [3][4][5].…”